The Science Fueling Cell Culture Optimization For Biologic Therapies

When demand for biologics outpaces your current manufacturing capacity, the instinct is often to invest in new equipment or expand your facility. But there's a faster, more cost-effective path: process intensification. By optimizing your existing fed-batch process, you can achieve meaningful productivity gains without the overhead of perfusion technology or infrastructure changes.

This research demonstrates how fine-tuning three key parameters, including initial feed amount, feed tapering during the stationary phase, and temperature shift timing, can dramatically increase IgG mAb titers in CHO cell culture. Using a 24-vessel Ambr 250 microbioreactor system and a custom design of experiments (DOE) framework, researchers evaluated these variables across two CHO K1 cell lines producing Rituximab and Herceptin. The results are compelling: titer increases of 63.2% and 64.3% were observed for Clone A and Clone B respectively, with Clone B reaching 11.01 g/L after intensification.

Critically, this approach proved consistent across two different molecules and clones, suggesting broad applicability within your biologics pipeline. The feed taper strategy, designed to limit excess nutrients during the stationary phase, played a key role in optimizing productivity while maintaining acceptable cell viability. Future work is extending this framework to more complex molecules, including Fc-fusion and bispecific antibodies.

If you're looking to get more from your existing capacity, this data-driven optimization strategy offers a practical blueprint. Download the poster now to review the full experimental design, prediction profiler outputs, and titer data for yourself.